Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9624268
APP PUB NO 20160145306A1
SERIAL NO

14800627

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease are described.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
PROTAGONIST THERAPEUTICS INC7707 GATEWAY BOULEVARD SUITE 140 NEWARK CA 94560

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bhandari, Ashok Pleasanton, US 54 873
Bourne, Gregory Thomas Jindalee, AU 24 307
Cheng, Xiaoli Mountain View, US 13 227
Frederick, Brian Troy Ben Lomond, US 32 514
Liu, David Milpitas, US 259 4773
Patel, Dinesh V Fremont, US 69 1312
Zhang, Jie Salisbury, AU 951 8111

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 18, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 18, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00